Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | RARA | P10276 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | THRA | P10827 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 3/20 | 0.65 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.61 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7329265 | 1.00 | RARB (0.77) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL28494516 | 0.88 | RARB (0.66) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL8536621 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL8533917 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL11113720 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL23484727 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL8531633 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL3088908 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL7542464 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL4174144 | 0.87 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296579-A1 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | CORNELL UNIVERSITY (US) | 2022-09-22 | — | — | US | disclosed |
| US-11191755-B2 | Compositions and methods for providing cardioprotective effects | CORNELL UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11160769-B2 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists | CORNELL UNIVERSITY (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3094380-B1 | METHODS OF TREATING METABOLIC SYNDROME RELATED CONDITIONS USING RETINOIC ACID RECEPTOR AGONISTS | UNIV CORNELL (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1907347-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | Arcadia Pharmaceuticals Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296579-A1 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | RARB, RARG, RARA | RARB 1/4885MEN1 4881/4885ALDH1A1 214/4885 |
| US-11191755-B2 | Compositions and methods for providing cardioprotective effects | RARB, RARG, RARA | RARB 1/4885MEN1 4881/4885ALDH1A1 214/4885 |
| US-11160769-B2 | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists | RARA, RARG, RXRA | RARB 5/4885MEN1 3112/4885ALDH1A1 316/4885 |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | RARB, RARA, RARG | RARB 1/4885MEN1 4845/4885ALDH1A1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.